FY2024 EPS Estimates for Generation Bio Boosted by Analyst

Generation Bio Co. (NASDAQ:GBIO - Free Report) - Stock analysts at Wedbush raised their FY2024 earnings per share (EPS) estimates for Generation Bio in a research note issued on Thursday, November 7th. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.96) per share for the year, up from their prior forecast of ($1.97). Wedbush has a "Outperform" rating and a $5.00 price objective on the stock. The consensus estimate for Generation Bio's current full-year earnings is ($1.85) per share. Wedbush also issued estimates for Generation Bio's Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.82) EPS.

Separately, Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Generation Bio in a research note on Wednesday, October 23rd.

Generation Bio Price Performance

Generation Bio stock traded down $0.08 on Monday, reaching $2.18. The company's stock had a trading volume of 211,891 shares, compared to its average volume of 181,466. The business's fifty day moving average price is $2.40 and its 200 day moving average price is $2.73. Generation Bio has a twelve month low of $1.06 and a twelve month high of $4.65.

Hedge Funds Weigh In On Generation Bio

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Generation Bio by 28.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,878,361 shares of the company's stock valued at $36,136,000 after acquiring an additional 1,952,187 shares during the period. Acadian Asset Management LLC lifted its stake in Generation Bio by 113.9% in the first quarter. Acadian Asset Management LLC now owns 479,835 shares of the company's stock valued at $1,952,000 after buying an additional 255,468 shares during the period. Bellevue Group AG lifted its stake in Generation Bio by 6.8% in the first quarter. Bellevue Group AG now owns 3,861,575 shares of the company's stock valued at $15,717,000 after buying an additional 244,495 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Generation Bio in the first quarter valued at about $74,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Generation Bio by 91.0% in the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company's stock valued at $54,000 after buying an additional 9,075 shares during the period. Institutional investors and hedge funds own 95.22% of the company's stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.